ABSTRACT: Assessment of fecal calprotectin, a surrogate marker of mucosal inflammation, is a promising means to monitor therapeutic response in pediatric inflammatory bowel disease, especially if the result is readily available. We tested the performance of a novel calprotectin rapid test, Quantum Blue, versus the conventional enzyme-linked immunosorbent assay in 134 stool samples from 56 pediatric patients with Crohn disease. The intraclass correlation coefficient analysis reflected good agreement (intraclass correlation coefficient 0.97 [95% confidence interval 0.95–0.98]) but agreement was better in lower values, where dilutions were not required. Using a cutoff of 100 μg/g for normal values, the percentage agreement between the 2 tests was 87%. The optimal cutoff values to guide clinical decisions in the therapy of inflammatory bowel disease have yet to be determined.
*Children's Hospital, Helsinki University Central Hospital, University of Helsinki, Helsinki, Finland
†Pediatric Gastroenterology Unit, Shaare Zedek Medical Center, Hebrew University of Jerusalem, Israel
‡Pediatric Gastroenterology Unit, University Hospital UZ Brussels, Belgium
§Polish-American Children's Hospital, Jagiellonian University School of Medicine, Krakow, Poland
||Pediatric Gastroenterology Unit, Erasmus MC-Sophia Children's Hospital, Rotterdam, The Netherlands
¶Meyer Children's Hospital, Rambam Medical Center, Haifa, Israel
#Department of Pediatrics, Hvidovre Hospital, Hvidovre, Denmark
**Department of Pediatrics, Hospital, S. Joao, Porto, Portugal
††Dr von Haunersches Kinderspital, Ludwig Maximilians University Munich, Munich, Germany
‡‡Department Pediatrics, La Sapienza Hospital, Rome
§§Edmon & Lili Safra Children's Hospital, Sheba Medical Center, Tel Aviv University, Tel Aviv, Israel
||||Department of Pediatrics, University of Naples “Federico II,” Naples, Italy
¶¶Department of Pediatric Gastroenterology and Nutrition, Medical University of Warsaw, Warsaw, Poland
##Unger-Vetlesens Institute, Lovisenberg Diakonale Hospital, Oslo, Norway
***Pediatric Gastroenterology Unit, Wolfson Medical Center, Sackler School of Medicine, Tel Aviv University, Tel Aviv, Israel
†††1st Department of Pediatrics, Semmelweis University, Budapest, Hungary.
Address correspondence and reprint requests to Kaija-Leena Kolho, MD, PhD, Children's Hospital, University of Helsinki, Box 281, FIN-00029 HUS, Helsinki, Finland (e-mail: firstname.lastname@example.org).
Received 16 October, 2011
Accepted 23 February, 2012
The present study received financial support from European Crohn's and Colitis Organization (A.L.), Finnish Pediatric Research Foundation Helsinki (K.L.K.), and University Central Hospital Research Fund (K.L.K.).
The authors report no conflicts of interest.